Biotronik’s Pantera Lux balloon shows effectiveness in trial

Biotronik has published new clinical trial data that showcases the potential benefits of its Pantera Lux paclitaxel-releasing balloon.

The device has demonstrated excellent safety and efficacy in a six-month trial called Pepper, which involved more than 1,000 patients from the international Delux registry who are affected by restenotic coronary artery lesions.

Following completion of the trial, it was shown that Biotronik's product was able to reduce rates of death and non-fatal myocardial infarction, while meeting expectations in terms of clinically driven target vessel revascularisation.

Pantera Lux is designed for use after drug-eluting or bare metal stenting and utilises the manufacturer's highly deliverable Pantera semicompliant balloon technology.

Alain Aimonetti, vice-president of sales and marketing at Biotronik's vascular intervention division, said: "These extremely favourable outcomes demonstrate success in both in-stent restenosis and de novo lesions with the emerging drug-eluting balloon technology."

This follows last month's launch of two new Pulsar-18 medical stents from Biotronik for the treatment of superficial femoral artery and below-the-knee conditions.